ArticleAntioxidants (Basel, Switzerland)2026
Endothelial Nitric Oxide Synthase-Dependent Mechanism of Hydroxyurea-Induced S-Phase Arrest in Erythroid Cells.
Article in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Hydroxyurea (HU) is a ribonucleotide reductase inhibitor widely used for the treatment of sickle cell disease and myeloproliferative disorders, yet a precise nitric oxide (NO) synthase (NOS)-dependent mechanism remains incompletely defined. The role of NOS3 in HU-mediated proliferation, cell cycle, and apoptosis was analyzed in HEL92.1.7 erythroleukemic cells and primary mouse erythroid progenitors upon genetic knockdown/knockout and pharmacological NOS2/NOS3 inhibition. NOS3 expression, phosphorylation, NO and citrulline production, and protein nitrosylation were assessed via immunoblotting and biochemical assays. Computational docking and molecular dynamics simulations were performed to examine the interaction between HU and NOS3. HU enhanced NOS3 expression and phosphorylation, leading to increased NO and citrulline production. Computational analysis predicted HU binding within the NOS3 active site, whereas functional activation was AKT1-dependent. A biotin switch assay revealed cooperative NOS2-/NOS3-mediated protein nitrosylation under HU treatment. NOS3 depletion or inhibition abrogated HU-induced S-phase accumulation and restored cell proliferation. NOS3 protein depletion increased late apoptosis in erythroleukemic cells, while in murine erythroid cells, both Nos3 deficiency and inhibition decreased early and increased late apoptosis. NOS2 and NOS3 act as complementary mediators of proliferation and apoptosis, with NOS3 playing a distinct role in HU-induced proliferation arrest in erythroid cells. These findings highlight the therapeutic potential of NOS targeting to enhance the efficacy of HU and overcome resistance in hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.